People
Henry Skinner
Henry Skinner is the Chief Executive Officer of the AMR Action Fund, with a background in microbiology, drug-development investing and pharmaceutical business development. His current own biography confirms prior leadership at Tekla Capital Management and Novartis Venture Fund and CEO roles at SelectX and NeoGenesis Pharmaceuticals. He earned a microbiology PhD and biochemistry MS at the University of Illinois, with additional bioethics/health-law training. Arkuda’s archived2021 company biography names him as a board member and then Tekla Senior Vice President of Venture; the Arkuda affiliation and Tekla title are historical, not assertions of current employment.
Roles
Board Member (archived company roster; historical, current status unverified)
Senior Vice President, Venture — former